About: Casimersen     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : dbo:Drug, within Data Space : dbpedia.org associated with source document(s)
QRcode icon
http://dbpedia.org/describe/?url=http%3A%2F%2Fdbpedia.org%2Fresource%2FCasimersen&graph=http%3A%2F%2Fdbpedia.org&graph=http%3A%2F%2Fdbpedia.org

Casimersen, sold under the brand name Amondys 45, is an antisense oligonucleotide medication used for the treatment of Duchenne muscular dystrophy (DMD) in people who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping. It is an antisense oligonucleotide of phosphorodiamidate morpholino oligomer (PMO). Duchenne muscular dystrophy is a rare disease that primarily affects boys. It is caused by low levels of a muscle protein called dystrophin. The lack of dystrophin causes progressive muscle weakness and premature death.

AttributesValues
rdf:type
rdfs:label
  • Casimersen (en)
  • Casimersen (de)
  • Касимерсен (ru)
rdfs:comment
  • Casimersen ist ein Arzneistoff aus der Gruppe der Antisense-Therapeutika. Als Amondys 45 wurde es im Februar 2021 in den USA zur Behandlung einer bestimmten genetischen Ausprägung der Duchenne-Muskeldystrophie (DMD) zugelassen. (de)
  • Касимерсен — лекарственный препарат для лечения мышечной дистрофии Дюшенна. Одобрен для применения: США (2021). (ru)
  • Casimersen, sold under the brand name Amondys 45, is an antisense oligonucleotide medication used for the treatment of Duchenne muscular dystrophy (DMD) in people who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping. It is an antisense oligonucleotide of phosphorodiamidate morpholino oligomer (PMO). Duchenne muscular dystrophy is a rare disease that primarily affects boys. It is caused by low levels of a muscle protein called dystrophin. The lack of dystrophin causes progressive muscle weakness and premature death. (en)
dcterms:subject
Wikipage page ID
Wikipage revision ID
Link from a Wikipage to another Wikipage
Link from a Wikipage to an external page
sameAs
dbp:wikiPageUsesTemplate
ATC suffix
  • AX13 (en)
ATC prefix
  • M09 (en)
c
CAS number
class
DrugBank
  • DB14984 (en)
H
KEGG
  • D11988 (en)
legal US
  • Rx-only (en)
n
O
p
routes of administration
synonyms
  • SRP-4045 (en)
tradename
  • Amondys 45 (en)
UNII
  • X8UHF7SX0R (en)
has abstract
  • Casimersen, sold under the brand name Amondys 45, is an antisense oligonucleotide medication used for the treatment of Duchenne muscular dystrophy (DMD) in people who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping. It is an antisense oligonucleotide of phosphorodiamidate morpholino oligomer (PMO). Duchenne muscular dystrophy is a rare disease that primarily affects boys. It is caused by low levels of a muscle protein called dystrophin. The lack of dystrophin causes progressive muscle weakness and premature death. The most common side effects include upper respiratory tract infections, cough, fever, headache, joint pain and throat pain. Casimersen was approved for medical use in the United States in February 2021, and it is the first FDA-approved targeted treatment for people who have a confirmed mutation of the DMD gene that is amenable to skipping exon 45. (en)
  • Casimersen ist ein Arzneistoff aus der Gruppe der Antisense-Therapeutika. Als Amondys 45 wurde es im Februar 2021 in den USA zur Behandlung einer bestimmten genetischen Ausprägung der Duchenne-Muskeldystrophie (DMD) zugelassen. (de)
  • Касимерсен — лекарственный препарат для лечения мышечной дистрофии Дюшенна. Одобрен для применения: США (2021). (ru)
DailyMedID
  • Casimersen (en)
prov:wasDerivedFrom
page length (characters) of wiki page
alternative name
  • Amondys 45 (en)
CAS number
  • 1422958-19-7
DrugBank
  • DB14984
FDA UNII code
  • X8UHF7SX0R
KEGG
  • D11988
class
foaf:isPrimaryTopicOf
is Link from a Wikipage to another Wikipage of
is Wikipage redirect of
is foaf:primaryTopic of
Faceted Search & Find service v1.17_git139 as of Feb 29 2024


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 08.03.3330 as of Mar 19 2024, on Linux (x86_64-generic-linux-glibc212), Single-Server Edition (61 GB total memory, 42 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software